Akava Therapeutics, Inc.

Akava Therapeutics, Inc. is dedicated to pioneering first-in-class inhibitory therapeutics for neurodegenerative diseases and cancer, holding tremendous promise for improving patient outcomes. With a strong foundation in groundbreaking research, Akava Therapeutics, Inc. is committed to addressing unmet medical needs and enhancing the quality of life for individuals facing these challenging conditions.

Akava Therapeutics, Inc. is developing innovative small molecule compounds with a focus on mechanism-focused and cellular-based drug discovery approaches. Their lead compound, AKV9, is currently being developed for amyotrophic lateral sclerosis (ALS) and has demonstrated potential in preclinical models of Alzheimer’s disease (AD). AKV9 uniquely targets upper motor neurons (UMN), which are critical in the early stages of neurodegeneration, and shows promise in improving the function and health of diseased UMN in ALS models. The company is also actively creating new analogs of AKV9 to explore their potential in treating other neurodegenerative diseases.

Akava Therapeutics, Inc. received Orphan Drug Designation status for AKV9 for the treatment of ALS from the FDA, underscoring the significance of their work. The company continues to advance its research and development efforts, aiming to bring novel therapies to patients in need. We encourage the management team at Akava Therapeutics, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.